KZR Kezar Life Sciences Inc.

8.16
0  0%
Previous Close 8.16
Open
Price To Book 1.53
Market Cap 156,014,475
Shares 19,119,421
Volume 0
Short Ratio
Av. Daily Volume 113,898

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Initial Phase 1b top-line data released May 28, 2019.
KZR-616
Lupus
Phase 1 initiation announced March 6, 2019.
KZR-616
Healthy volunteers
Phase 2 trial to be initiated 2Q 2019.
KZR-616
Lupus nephritis (LN)
Phase 2 trial to be initiated 2H 2019.
KZR-616
Autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP)
Phase 2 trial to be initiated 2H 2019.
KZR-616
Dermatomyositis and polymyositis

Latest News

  1. The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA
  2. Kezar Life Sciences Announces Promising Data from First in Patient Study of KZR-616 at EULAR 2019 Annual Meeting
  3. Kezar Life Sciences to Host Conference Call and Webcast at the EULAR 2019 Annual Meeting to Discuss Results of First in Patient Study with KZR-616
  4. The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation
  5. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Kezar Life Sciences, Inc. - KZR
  6. Kezar Life Sciences Announces Acceptance of Abstract for Presentation of First in Patient Study with KZR-616 at EULAR 2019 Annual Meeting
  7. Did Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Buy Up More Shares?
  8. Health Care Digest: Cancer's show-and-tell meeting, a new biotech building rises and lupus patients' plea
  9. Kezar Life Sciences Announces Presentations at Two Upcoming Investor Conferences
  10. Here is What Hedge Funds Think About Kezar Life Sciences, Inc. (KZR)
  11. Kezar Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update
  12. Kezar Life Sciences to Present at the 18th Annual Needham Healthcare Conference
  13. Kezar Life Sciences Announces Presentations at Upcoming Scientific Conferences
  14. Kezar Life Sciences Reports Fourth Quarter and Year End 2018 Financial Results and Provides Business Update
  15. Kezar Life Sciences Announces Initiation of Clinical Study to Test a New Drug Product Formulation of KZR-616
  16. Kezar Life Sciences to Present at the Cowen and Company 39th Annual Health Care Conference
  17. Kezar Life Sciences Strengthens Management Team, Appoints Celia Economides as Senior Vice President, Strategy and External Affairs
  18. These 4 Biotech Stocks are Picking Up Speed
  19. Kezar Life Sciences to Present at The BMO Prescriptions for Success Healthcare Conference
  20. Here's how much better insiders have profited from this year's IPO boom